Jing Wang

发表

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

C. Crews, Y. Qian, K. Coleman, 2015, Chemistry & biology.

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

C. Crews, Y. Qian, K. Coleman, 2016, Proceedings of the National Academy of Sciences.

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.

Jing Wang, Yimin Qian, George M Burslem, 2017, Cell chemical biology.

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance

C. Crews, T. Neklesa, D. McDonnell, 2018, Communications Biology.

The crystal structure of a constitutively active mutant RON kinase suggests an intramolecular autophosphorylation hypothesis.

S. Steinbacher, M. Augustin, D. Epstein, 2010, Biochemistry.

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.

C. Crews, Daniel P. Bondeson, A. Ishchenko, 2017, Cell chemical biology.

ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.

I. Taylor, C. Crews, T. Neklesa, 2019, Journal of Clinical Oncology.

Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer

I. Taylor, C. Crews, T. Neklesa, 2018, Clinical Research (Excluding Clinical Trials).

An oral androgen receptor PROTAC degrader for prostate cancer.

I. Taylor, C. Crews, T. Neklesa, 2017 .

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

X. Chen, T. Januario, M. Merchant, 2022, Nature Communications.

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.

Yevgeniy V. Serebrenik, D. Vigil, C. Crews, 2017, Journal of medicinal chemistry.

Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.

D. Werner, P. Gokhale, N. Gibson, 2011, Bioorganic & medicinal chemistry letters.

Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.

Jing Wang, E. Buck, M. Mulvihill, 2012, Future medicinal chemistry.

Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.

D. Epstein, Jing Wang, A. Crew, 2013, Bioorganic & medicinal chemistry letters.

Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer

C. Crews, T. Neklesa, I. Taylor, 2021, Experimental and Molecular Therapeutics.

Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1.

James G. Tarrant, M. Albertella, D. Berger, 2013, Bioorganic & medicinal chemistry letters.

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance

C. Crews, T. Neklesa, D. McDonnell, 2018, Communications Biology.

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.

M. Albertella, P. Gokhale, D. Epstein, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics.

M. Albertella, E. May, D. Romashko, 2013, Bioorganic & medicinal chemistry letters.